Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug309 | Anti-SARS-CoV-2 immunoglobulin Wiki | 1.00 |
| drug291 | Angiotensin II Wiki | 0.71 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D013577 | Syndrome NIH | 0.09 |
| D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.08 |
| D055371 | Acute Lung Injury NIH | 0.08 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
This study aims to find out whether the use of angiotensin II, which is a drug to raise blood pressure has been approved by European Medical Agency in August 2019, as an add-on medication to increase blood pressure in patients with COVID-19, acute severe lung injury, inflammation and severe shock, compared with standard medication. In addition, the investigators will collect the data of Anakinra, another drug which is frequently used in this condition to reduce inflammation. The investigators will collect clinical data and outcomes from critical care patients. The investigators will analyse for whom these drugs are most beneficial and explore whether there are any patients who don't benefit or have side effects.
Description: Percentage
Measure: Proportions of patients with mean arterial pressure ≥ 65 mmHg or an increase of mean arterial pressure ≥10 mmHg at 3 hours Time: 3 hoursDescription: microgram/kg/min
Measure: Noradrenaline dose Time: 1 hour and 3 hoursDescription: Changes in score, minimum 0, maximum 24, the higher score showing worse prognosis
Measure: Sequential Organ Failure Assessment (SOFA) score Time: baseline, 24, and 48 hoursDescription: Patients who are alive and do not require renal replacement therapy at 28 days
Measure: RRT-free days Time: 28 daysDescription: Proportions of patients who do not require renal replacement therapy
Measure: RRT discontinuation Time: 7 and 28 daysDescription: micromol/L
Measure: Serum creatinine Time: 7 days and 28 daysDescription: Changes in value
Measure: PaO2/FiO2 ratio Time: baseline, 24, and 48 hoursDescription: Mortality rate
Measure: Mortality Time: 7 days and 28 daysDescription: e.g. arrhythmia, thromboembolism, etc.
Measure: Adverse events Time: 28 daysDescription: Change in serum C-reactive protein
Measure: Change in serum C-reactive protein Time: 7 daysDescription: Change in serum ferritin
Measure: Change in serum ferritin Time: 7 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports